SCHEMBL5656572

SCHEMBL5656572

Cc1cccc2c1N(Cc1ccccc1Cl)C(=O)C2=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.60
MAPT P10636 9/20 0.59
TP53 P04637 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 8/20 0.52
CHRM5 P08912 4/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
LMNA P02545 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 3/20 0.51
TGM2 P21980 1/20 0.51
HTT P42858 1/20 0.51
HPGD P15428 2/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
ALOX12 P18054 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CHRM3 P20309 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656965 0.87 CHRM5 (0.53) L3MBTL1MAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL28070743 0.86 TP53 (0.51) L3MBTL1MAPTTP53SMN1; SMN2CHRM5
SCHEMBL18954698 0.80 MAPT (0.56) L3MBTL1MAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL12857524 0.79 CASP3 (0.65) MAPTSMN1; SMN2ALDH1A1CHRM5KMT2A
SCHEMBL4609842 0.78 CES1 (0.66) MAPTTP53ALDH1A1CHRM5KMT2A
SCHEMBL5659656 0.77 ACHE (0.66) L3MBTL1MAPTTP53ALDH1A1CHRM5
SCHEMBL10339317 0.75 TYR (0.64) MAPTSMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL30967409 0.75 CHRM5 (0.70) MAPTTP53ALDH1A1CHRM5HSD17B10
SCHEMBL18954872 0.75 CHRM5 (0.55) MAPTTP53ALDH1A1CHRM5KMT2A
SCHEMBL10973118 0.74 CHRM5 (0.74) L3MBTL1MAPTTP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 L3MBTL1 4599/4885MAPT 3588/4885TP53 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.